Pharma BD Deal Intelligence

Scipher Medicine / Chemomab Therapeutics Ltd.

2026 · Reverse Merger · Pending

Chemomab Therapeutics and precision-medicine company Scipher Medicine entered a definitive all-stock merger agreement to advance Chemomab's anti-CCL24 antibody nebokitug into an AI-guided Phase 2 trial in rheumatoid arthritis using Scipher's patient-stratification platform. Scipher shareholders are to hold approximately 68% of the combined company and Chemomab holders approximately 32% on a fully diluted basis, plus contingent value rights tied to nebokitug milestones. The transaction is accompanied by an approximately USD 30 million concurrent financing commitment. The combined company is expected to operate as Scipher Medicine Corporation and trade on Nasdaq under the ticker SCIP, with closing expected in the fourth quarter of 2026.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals